Skip to content

A clinical study of low-dose esketamine for the prevention and treatment of PPD in patients undergoing cesarean section

A clinical study of low-dose esketamine for the prevention and treatment of PPD in patients undergoing cesarean section

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065494
Enrollment
Unknown
Registered
2022-11-07
Start date
2022-11-20
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depression

Interventions

esketamine group:After delivery of the fetus with umbilical cord severed, 0.25 mg/kg of esketamine was administered intravenously and pumped for 40 minutes. The pumping was completed in 40 minutes.
Control Group:After delivery of the fetus with umbilical cord severed, give 0.05 ml/kg saline intravenous pumping, 40 minutes to complete the pumping

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Pregnant women aged 20-35 years who were to undergo cesarean section under epidural block for full-term singleton pregnancy; 2. Volunteered to join this study and obtained informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous history of mental illness or family history; 2. Pregnant women with complete/partial placenta praevia requiring general anesthesia; 3. Contraindications to epidural block, including poor coagulation, puncture site infection, significant lumbar spine injury, etc.; 4. Allergy to local anesthetics; 5. Severe pregnancy comorbidities, such as uncontrolled hypertension or diabetes mellitus during pregnancy, combined with severe cardiac, hepatic, and renal impairment.

Design outcomes

Primary

MeasureTime frame
Edinburgh postnatal depression scale (EPDS) score at 6 weeks postoperatively;

Countries

China

Contacts

Public ContactGangming Wu

The First Affiliated Hospital of Chongqing Medical University

459910606@qq.com+86 18323187421

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026